Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Complement C1q”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,369 records · Page 76Linked to original sources
PubMed1990

Development of a C1q-adsorbent for the selective removal of circulating immune complexes.

In body fluids circulating immune complexes possess a substantial pathogenic effect on a variety of diseases. Thus it seems to be reasonable to influence the pathogenic mechanism of such diseases by removing the circulating immune complexes out of the body fluids. The selective adsorbent for binding immune complexes were developed as possible alternative of plasmapheresis for specific removal of immune complexes out of the blood plasma. The principle is based on the biospecific binding of immune complexes to C1q that is immobilized by a covalent binding to different solid phases. Thus: so bound immune complexes can be separated by detaching the solid phases. The adsorbent may be regenerated by non-denaturated media and can be used manyfold. This adsorbent has a high biocompatibility and offers the possibility for clinical use.

Antigen-Antibody Complex↗
PubMed1999

The receptor for the globular "heads" of C1q, gC1q-R, binds to fibrinogen/fibrin and impairs its polymerization.

The 33-kDa cellular C1q binding protein, designated gC1q-R was previously shown to bind a number of plasma proteins involved in the coagulation and kinin systems. This study demonstrates the interaction between recombinant gC1q-R and fibrinogen. Using enzyme-linked immunosorbent assays, biotinylated gC1q-R was found to bind to microplate-immobilized fibrinogen in a manner which was specific and inhibited by excess soluble fibrinogen or polyclonal antibodies directed against either gC1q-R or fibrinogen. Moreover, gC1q-R inhibited fibrin polymerization in a dose-dependent manner. Reptilase induced fibrin clot formation was completely inhibited by gC1q-R at a 2:1 molar ratio (gC1q-R:fibrinogen), and repolymerization of thrombin induced fibrin monomers was similarly abrogated. At equivalent molar concentrations, gC1q-R appeared to be a more potent inhibitor of fibrin polymerization than fibrinogen, a well-known inhibitor. Moreover, in the presence of both gC1q-R and soluble fibrinogen, the effect of each inhibitor on fibrin polymerization was additive. When plasmin derived fibrinogen degradation products, including the C-terminal D domain (D-100) or the N-terminal E domain, were immobilized on microtiter plates, gC1q-R bound to fibrinogen fragment D-100, but not to fragment E. Further digestion of fibrinogen fragment D-100 by plasmin to fragment D-60 resulted in loss of gC1q-R binding. Thus, gC1q-R binds to the D domain of fibrinogen/fibrin, and the carboxyterminal segment of at least the fibrinogen/fibrin gamma chain appears important for this interaction. These observations may suggest a potential role for gC1q-R in modulating fibrin formation particularly at local sites of immune injury or inflammation.

Anticoagulants↗
PubMed1989

C1q binding to chimeric monoclonal IgG3 antibodies consisting of mouse variable regions and human constant regions with shortened hinge containing 15 to 47 amino acids.

We have constructed four different deletion mutants of a chimeric mouse-human IgG3 anti-(4-hydroxy-3-nitrophenyl)acetyl/(5-iodo-4 hydroxy-3 nitrophenyl) acetyl (NP/NIP) antibody lacking one or more of the four exons coding for the hinge region. The mutant variants all retained intact hinge region epitopes since they all reacted with IgG3 hinge-specific antibodies. Surprisingly, all the deletion mutants bound C1q equally well or even better than the wild type. Thus the high C1q binding activity of IgG3 compared to IgG1 is apparently not due to the total length of the IgG3 hinge, which is 62 amino acids, nor is it due to the length of the upper hinge which is the stretch from the end of CH1 to the first inter-heavy chain disulfide bond.

Amino Acid Sequence↗
PubMed1985

Selective losses of large immune complexes during density gradient ultracentrifugation and an approach for prevention of these losses.

Substantial amounts (12.3-40.0%) of model immune complexes became nonspecifically adsorbed to centrifuge tubes during sucrose density gradient ultracentrifugation, and the adsorbed complexes were therefore unavailable for subsequent detection by the C1q solid-phase assay. The adsorption was greater for heavier immune complexes; thus detection of large-latticed complexes was impaired more than detection of small-latticed complexes. Loss of complexes could be prevented by incorporation of 0.05% polyoxyethylene (20) sorbitan monolaurate (Tween 20) into sucrose density gradient solutions and precoating tubes with gelatin. Tween 20 did not alter the immune complex lattice and did not prevent detection of immune complexes by the C1q solid-phase assay. Similar selective losses of immune complexes occurred when serum specimens from 2 patients with circulating immune complexes were analyzed by sucrose density gradient ultracentrifugation; the nonspecific adsorption of serum immune complexes which occurred during ultracentrifugation could be prevented by precoating centrifuge tubes with gelatin and incorporating 0.05% Tween 20 into sucrose gradients.

Adsorption↗
PubMed1989

C1q and C1 subcomponent complexes in otitis-prone and non-otitis-prone children. A prospective study of children during their first years of life.

Children with recurrent acute otitis media (rAOM) often show reduced C1q concentrations and an excess of (C1r-C1s)2 complexes. It is not known if such C1 aberrations precede development of rAOM or are a consequence of the infections. For this reason, serial investigation of C1q and C1 subcomponent complexes from birth until the age of three was performed in 113 children, 13 of whom developed rAOM. C1q concentrations at birth were found to be lower in the rAOM group than in children who did not experience acute otitis media, and were also correlated with age at the time of the first AOM episode. However, the wide variation of C1q within the groups precluded the use of C1q as a predictive marker. Excess (C1r-C1s)2 complexes were consistently absent at birth. High concentrations were found in children with established otitis media and the complexes persisted in association with recurrent disease. In conclusion, the C1 aberrations characteristic of rAOM were mainly acquired as a result of infection.

Acute Disease↗
PubMed1992

Interaction of C1q receptor with lung surfactant protein A.

Earlier we reported the purification of C1q receptor (C1qR) from U937 cells and human tonsil lymphocytes (Malhotra, R. and Sim, R. B., Biochem. J. 1989. 218: 625) and showed that C1qR interacts with the ligands C1q, mannose-binding protein, conglutinin and lung surfactant protein A (SP-A) (Malhotra, R., Thiel, S., Reid, K. B. M. and Sim, R. B., J. Exp. Med. 1990. 172: 955). C1qR was characterized as an acidic glycoprotein, which, when solubilized, exists as a dimer of Mr 115,000 under non-denaturing conditions. In this article we provide evidence for binding of radioiodinated SP-A to U937 cells and show that binding of radioiodinated SP-A to U937 cells is specific, saturable, salt dependent and is inhibited by purified C1qR and by C1q. The interaction of SP-A with U937 cells was found to up-regulate the surface expression of C1qR. Incubation of SP-A with U937 cells at 37 degrees C for 80 min was found to increase the receptor number per cell. Increase in receptor number was inhibited in the presence of sodium azide and monensin. Incubation of cells with calcium ionophore A23187 induced increased surface expression in the absence of SP-A. The results indicate that interaction of SP-A with U937 cells triggers the expression of an intracellular pool of C1qR.

Amino Acid Sequence↗
PubMedDate not supplied

Characterization of radioiodinated lung surfactant protein A (SP-A) and the effects of oxidation on SP-A quaternary structure and activity.

Lung surfactant protein A (SP-A) is the most abundant surfactant-associated protein present in the lung and respiratory tract. SP-A binds to several pathogens via its C-type lectin domains, and may act as an opsonin, mediating adhesion to cells via the collectin receptor. Binding studies using SP-A are made difficult by its apparent instability following radioiodination. This study investigated the effect of oxidation (via radioiodination and exposure to H2O2) on the structural and functional characteristics of SP-A. Radioiodinated SP-A, stored at 4 degrees C, retained carbohydrate binding activity after labeling. After 10 days storage, the radioiodinated SP-A was indistinguishable on SDS-PAGE from freshly radioiodinated SP-A, but sedimentation coefficient and Stokes radius values changed dramatically, indicating SP-A depolymerization. Such a quaternary structural breakdown, with a concomitant reduction in carbohydrate binding activity, is likely to be due to oxidative cleavage of disulfide bonds. Comparable results were observed upon radioiodination of the structurally similar molecule C1q. Consequently, the effect of prolonged incubation with H2O2 upon SP-A was investigated, with similar results. Thus, exposure to oxidizing agents leads to breakdown of the hexameric quaternary structure of SP-A, often to native polypeptides, with an attendant loss of binding activity. Such an effect may have consequences for the physiological role of SP-A in the lung.

Complement C1q↗
PubMedDate not supplied

T and B lymphocytes, immunoglobulins and complement components in bronchial asthma.

Sixty children, 7--15 years old, suffering from bronchial asthma and 44 healthy children, 12--14 years old, were studied for the percentage and the total count per mm.3 of T and B lymphocytes. Patients were classified into extrinsic atopic, mixed and intrinsic asthma. According to the clinical course mild and severe cases were analysed separately. The total and "active" T lymphocytes were detected by the ability to form nonimmune rosettes with sheep red blood cells. The B lymphocytes were estimated by the rosetting procedure with antibody mouse complement coated sheep erythrocytes. No decrease of the percentage or total count of T lymphocytes was observed, and an elevation of total count and percentage of active T cell rosettes was even seen in severe cases of extrinsic atopic asthma. The B cell percentage was decreased in severe atopic, mild intrinsic and mild mixed asthma but the total number was lowered only in the last group. The immunoglobulin A, G, M, D and E level, measured by the single radial immunodifussion test, was correlated neither to T cell nor B cell percentage. The complement components C1q, C4, C3, C3 proactivator and C5 were measured by the radial immunodufusion test in the plasma of some patients and controls. The C1q level was normal. An elevation of C4 in mild extrinsic, C5 in severe extrinsic and C3 in severe mixed asthma was seen. A decrease of C3 proactivator was observed in mild extrinsic and mixed asthma, and in three cases of intinsic asthma this was accompanied by lowering of C3, suggesting an activation of the alternative pathway.

Adolescent↗
PubMed1983

Presence of circulating immune complexes in patients with peripheral corneal disease.

Seventeen patients with peripheral corneal thinning and ulcers (four with Mooren's corneal ulcer, five with Terrien's marginal degeneration, and eight with collagen vascular disease) were tested for immune complexes in their serum. Circulating immune complexes, measured by Raji cell and C1q binding assays, were compared with levels in serum samples from normal controls and seven patients with staphylococcal marginal corneal ulcers. Comparison with normal controls showed significantly higher levels of circulating immune complexes in patients with collagen disease by the C1q binding assay and in patients with Mooren's ulcer by the Raji cell assay. Circulating immune complexes may play a role in the pathogenesis of Mooren's ulcer and marginal ulceration in the presence of collagen vascular disease. Their presence, however, may represent an epiphenomenon nonspecifically associated with corneal ulceration.

Adolescent↗
PubMed1989

C1q binding to human vascular smooth muscle cells mediates immune complex deposition and superoxide generation.

Evidence was obtained for the binding of C1q to the membrane of cultured vascular smooth muscle cells derived from human umbilical cord veins. C1q was fixed to the cell membrane at 4 degrees C, whereas it was ingested into the cytoplasm, as a cytoplasmic inclusion, when tested at 37 degrees C. The addition of C1q in advance inhibited the subsequent binding of C1q. Neither fibronectin nor laminin was detected on the cell membrane. Aggregated IgG bound to vascular smooth muscle cells in the case of preincubation with C1q at 4 degrees C, whereas aggregated IgG did not bind to the cells in the absence of C1q. The addition of C1q molecules to the cells in suspension enhanced superoxide generation by vascular smooth muscle cells. There was no effect of C1q on superoxide generation by the cells in monolayer. These results suggest that C1q binds on the membrane of vascular smooth muscle cells via its specific receptor that mediates immune complex binding to the cells and superoxide generation. These properties elucidate the mechanisms by which circulating immune complexes deposit in the vascular wall, and subsequent degradation of tissue components surrounding vascular smooth muscle cells occurs through oxidative burst of the cells.

Antigen-Antibody Complex↗
PubMed1990

Protective and inactivating effects of neutrophil myeloperoxidase on C1q activity.

This study investigated the interaction between neutrophil myeloperoxidase (MPO) and the C1q component of the complement system. Using a dot-spot assay, MPO was found to bind to C1q in a dose-dependent manner. The specificity of this reaction was proved by the inhibitory effect of F(ab')2 antibodies to C1q and by the inability of MPO to bind to C1r, C1s and IgG. The interaction between MPO and C1q did not influence the enzymatic activity of the peroxidase but resulted in a more stable C1q as assessed by hemolytic assay for C1q. The protective effect of MPO on C1q did not require the presence of H2O2 in the reaction mixture nor was it inhibited by sodium azide, whereas it was abolished by heating the peroxidase. Lactoferrin and lysozyme, unlike MPO, were ineffective in protecting C1q from functional decay. Addition of H2O2 and chloride to MPO and C1q led to a complete inactivation of C1q, which could not be induced by H2O2 alone. The hypochlorite, which is known to be generated during the reaction of MPO with H2O2 and chloride, exhibited a similar inactivating effect on C1q, which was prevented by an external source of methionine.

Chlorides↗
PubMed2001

Soluble gC1q-R/p33, a cell protein that binds to the globular "heads" of C1q, effectively inhibits the growth of HIV-1 strains in cell cultures.

C1q and the outer envelope protein of HIV, gp120, have several structural and functional similarities. Therefore, it is plausible to assume that proteins that are able to interact with C1q may also interact with isolated gp120 as well as the whole HIV-1 virus. Based on this hypothesis, we studied the potential ability of the recombinant form of the 33-kDa protein, which binds to the globular "heads" of C1q (gC1q-R/p33), to inhibit the growth of different HIV-1 strains in cell cultures. gC1q-R/p33 was found to effectively and dose-dependently inhibit the production of one T-lymphotropic (X4) and one macrophage-tropic (R5) strain in human T cell lines (MT-4 and H9) and human monocyte-derived macrophage cultures, respectively. At a concentration range of 5-25 microg/ml, gC1q-R caused a marked and prolonged suppression of virus production. The extent of inhibition was enhanced when gC1q-R was first incubated with and then removed from the target cell cultures before virus infection, compared to that when the cells were infected with gC1q-R-HIV mixtures. The extent of inhibition was comparable to that of the Leu3a anti-CD4 antibody. Addition of gC1q-R to the cell cultures on day 1 or 2 after infection induced markedly less inhibition of HIV-1 growth than pretreatment of the cells just before or together with the infective HIV strains. In ELISA experiments, gC1q-R did not bind to a solid-phase recombinant gp120 while strong and dose-dependent binding of gC1q-R to solid-phase CD4 was observed. Our present findings indicate that gC1q-R is an effective inhibitor of HIV-1 infection, which prevents viral entry by blocking the interaction between CD4 and gp120. Since gC1q-R is a human protein, it is most probably not antigenic in humans. It would seem logical, therefore, to consider gC1q-R or its fragments involved in the CD4 binding as potential therapeutic agents.

Anti-HIV Agents↗
PubMed2003

Bartter syndrome complicated by immune complex nephropathy. Case report and literature review.

The unusual coincidence of Bartter syndrome and C1q nephropathy is described and the literature reviewed. An African-American girl presented at 4 years of age with acute hyponatremic dehydration and failure to thrive. Persistent hypokalemic alkalosis and secondary hyperaldosteronism were found. The case was atypical for Bartter syndrome in that proteinuria (0.19 g/day) was present. Renal biopsy showed juxtaglomerular hyperplasia and C1q nephropathy. Molecular analysis showed deletion of the renal chloride channel gene (CLCNKB) typical of autosomal recessive childhood Bartter syndrome. Chronic sodium and potassium chloride replacement therapy together with indomethacin normalized her metabolic status, and she experienced catch-up growth. Proteinuria persisted, however. This is the first documentation of C1q nephropathy, in mild form, complicating autosomal recessive Bartter syndrome. This case shows the importance of the renal biopsy and of molecular analysis in delineating the cause of atypical nephropathy associated with Bartter syndrome. These findings add to the evidence of a possible association between the congenital syndrome and acquired immune complex nephropathy.

Anion Transport Proteins↗
PubMed1975

The role of complement, immunoglobulin and bacterial antigen in coagulase-negative staphylococcal shunt nephritis.

We describe three patients with arrested hydrocephalus in whom glomerulonephritis developed secondary to Staphylococcus epidermidis bacteremia from an infected ventriculoatrial shunt. Investigation of the immune-mediated renal disease associated with this chronic infection showed that (1) complement depletion during the acute phase of bacteremia and nephritis was predominantly via the classic pathway; (2) rheumatoid factor was associated with bacteremia, fever, proteinuria and low complement levels; (3) early complement components (C1q, C4, C3), immunoglobulin (predominantly immunoglobulin M [IgM], Staph. epidermidis antigen(s) and electron denxe subendothelial deposits were localized within the renal glomerulus; (4) C1q, and IgM derived from patient serums, were the most prominent in vitro immunoreactants to Staph. epidermidis cell walls; and (5) the causative organisms, Staph. epidermidis, shared common antigens with Staph. aureus, and antibody from patient serums cross reacted with extracts from both of these organisms.

Antigens, Bacterial↗
PubMed2000

Experimental lupus nephritis in severe combined immunodeficient (SCID) mice: remodelling of the glomerular lesions by bystander IgM antibodies.

MRL/Mp-lpr/lpr (MRL/lpr) mice develop glomerular lesions with regular variations in their histopathological manifestations, similar to those in lupus nephritis. These lesions are mainly either cell-proliferative or wire loop-like and are associated with glomerular deposits of immunoglobulins, most frequently IgG and IgM. We previously established a nephritogenic IgG3-producing hybridoma clone, B1, from an MRL/lpr mouse, which induces only a 'wire loop-like' type of glomerular lesion when injected into SCID mice. Injection of SCID mice with an anti-trinitrophenyl IgM antibody-producing hybridoma clone, Sp6, following injection of the B1 clone, however, resulted in the development of a 'cell-proliferative' type of glomerular lesion, associated with an accumulation of both antibodies in glomeruli. This accumulation occurred even though Sp6 IgM antibodies did not react with B1 IgG3 antibodies and vice versa. A mutant clone of Sp6, T/13microE/3.1, which produces antibodies deficient in C1q binding, produced a similar effect as that of the Sp6 clone, i.e. 'cell-proliferative' lesions. Again the B1 antibodies did not react with T/13microE/3. 1-IgM antibodies and vice versa. We therefore conclude that bystander IgM antibodies contribute to the remodelling of glomerular lesions in situ, following glomerular injury by the nephritogenic antibodies.

Animals↗
PubMed1998

Structure and function of gC1q-R: a multiligand binding cellular protein.

gC1q-R is a 33 kDa, single chain, highly acidic protein, which was first isolated from membrane preparation of Raji cells and now appears to be ubiquitously distributed. Although, gC1q-R was originally identified as a protein which binds to the globular "heads" of C1q, recent evidence suggests that the molecule is in fact a multiligand binding, multifunctional protein with affinity for diverse ligands which at best are functionally related. These molecules include: thrombin, vitronectin, and high molecular weight kininogen. The gC1q-R molecule, which is identical to the transcription factors SF2 and the Tat-associated protein, or TAP, is the product of a single gene localized on chromosome 17p13.3 in human, and chromosome 11 in mouse, and is encoded by an approximately 1.5-1.6 kb mRNA. The full length cDNA encodes a primary translation protein of 282 residues and the 'mature' or membrane form of the protein isolated from Raji cells corresponds to residues 74-282 and is presumed to be generated by a site-specific cleavage and removal of the highly basic, 73-residues long, N-terminal segment during post-translational processing. The translated amino acid sequence does not predict for the presence of a conventional sequence motif compatible with a transmembrane segment and does not have a consensus site for a GPI anchor. However, there is strong evidence which indicates that gC1q-R is expressed both inside the cell and on the membrane. First, certain mAbs raised against gC1q-R react moderately with intact Raji cells in suspension and this binding increases when the cells are first bound to poly-L-lysine coated surfaces and then fixed with glutaraldehyde. Second, surface labeling of cells using the membrane impermeable sulfo-NHS-LC-biotin shows that gC1q-R on the surface incorporates biotin whereas intracellular gC1q-R does not. In addition, the membrane expression of gC1q-R can be upregulated with inflammatory cytokines such as INF-gamma, TNF-alpha, or LPS. These results suggest, that gC1q-R, is localized both as an intracellular and as a cell surface protein and may have important biological functions in both compartments of the cell.

Animals↗
PubMed1983

Critical aspects of immune complex assays employing polyethylene glycol.

Treatment of artificial immune complexes (ICs) with 2.5% polyethylene glycol (PEG)--conditions under which C1q-binding activity is routinely measured in the fluid phase--produced marked changes in molecular size as determined by Sepharose 6B chromatography. The effect of PEG on the C1q-binding capacity of ICs, was therefore investigated using a solid phase (SP) system. PEG enhanced the binding of aggregated human gammaglobulin (AHG) and artificial ICs to SP-C1q and, in reverse experiments, also increased the binding of C1q to SP-AHG. The degree of enhancement varied according to the Ag:Ab ratio employed; the binding of ICs formed in moderate Ab excess was only modestly enhanced but that of complexes formed at slight Ab excess, equivalence and Ag excess was markedly elevated. The profile of PEG-induced enhancement of binding paralleled that of similar ICs in the C1q fluid phase system, suggesting that C1q binding in the latter may be influenced by PEG. However, the C1q-binding activity of in vivo-formed ICs seemed to be relatively unaffected by PEG since enhanced binding was comparable in control and pathological sera. The results indicate that PEG causes cross-linking and aggregation of ICs (and possibly other serum proteins) which may alter their biological activity and hence influence the results of IC assays that employ this agent.

Antigen-Antibody Complex↗
PubMed1998

The soluble recombinant form of a binding protein/receptor for the globular domain of C1q (gC1qR) enhances blood coagulation.

The gC1qR is a ubiquitously expressed, 33 kDa cellular protein which recognizes the globular domains of C1q. Recent evidence suggests that the gC1qR also serves as the Zn(++)-dependent endothelial cell binding site for factor XII and high-molecular-weight kininogen, and activates intrinsic coagulation and kinin pathways in purified systems. In addition, activated lymphocytes have been reported to release soluble gC1qR. Thus, the present study investigated the procoagulant potential of soluble gC1qR in human plasma using the recombinant protein (rgC1qR). rgC1qR supported a dose-dependent shortening of extrinsic coagulation using the prothrombin time in the presence of diluted (1/50-1/500) thromboplastin. Maximum enhancement of the prothrombin time resulted in shortening of the clotting time from 78.8 +/- 0.4 s to 68.5 +/- 0.6 s (mean +/- SD, n = 8) in the presence of 50 micrograms/ml (1.5 mumol/l) rgC1qR. rgC1qR also enhanced the intrinsic pathway of coagulation evaluated in the absence of activators of the contact system, as demonstrated by a shortening of the plasma recalcification time from 348 +/- 66 s to 140 +/- 23 s (n = 4). rgC1qR, however, had no effect on intrinsic coagulation in the presence of undiluted kaolin or ellagic acid, and under these conditions failed to shorten the activated partial thromboplastin time of factor VIII or factor-IX-deficient plasma. rgC1qR further failed to affect thrombin and factor Xa generation assayed using chromogenic substrates, and did not enhance thrombin-induced conversion of fibrinogen to fibrin. Interestingly, the procoagulant activity of the rgC1qR was measurable in either factor-XII- or factor-XI-deficient plasma, suggesting that it was not exclusively focused on the contact system of coagulation. Although the mechanism of action of gC1qR on blood coagulation remains obscure, the data suggest a potential role for this protein in hemostatic and thrombotic events.

Blood Coagulation↗